---
title: "Daré Bioscience Posts Updated Corporate Investor Presentation Online"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283676038.md"
description: "Daré Bioscience, Inc. has updated its corporate investor presentation, available on its website and as part of a regulatory filing. The materials are for informational purposes only and not filed under U.S. securities laws. The latest analyst rating for DARE stock is a Buy with an $8.00 price target, but Spark's AI Analyst rates it as Neutral due to weak financial performance and funding risks. Daré focuses on women's health and engages with investors through regular updates."
datetime: "2026-04-22T13:28:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283676038.md)
  - [en](https://longbridge.com/en/news/283676038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283676038.md)
---

# Daré Bioscience Posts Updated Corporate Investor Presentation Online

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Daré Bioscience ( (DARE) ) has issued an update.

On April 22, 2026, Daré Bioscience, Inc. made an updated corporate presentation available in the investors section of its website, also furnishing the deck as an exhibit to a regulatory filing. The company emphasized that the materials are being provided for informational purposes only and are not deemed filed under U.S. securities laws, limiting their use in future securities-related proceedings or regulatory incorporations by reference.

The most recent analyst rating on (DARE) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

**Spark’s Take on DARE Stock**

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

The score is primarily held back by weak financial performance—large losses, significant 2025 cash burn, and ongoing funding/dilution risk. Technicals are supportive but appear overbought, while valuation remains constrained by unprofitability. The earnings call adds some support due to positive pipeline/launch milestones and cash on hand, but capital limitations and higher expenses temper the outlook.

To see Spark’s full report on DARE stock, click here.

**More about Daré Bioscience**

Daré Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products, with an emphasis on women’s health. The company targets investors and stakeholders in the life sciences and healthcare sectors through regular corporate updates and investor communications.

**Average Trading Volume:** 333,018

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $41.79M

For an in-depth examination of DARE stock, go to TipRanks’ Overview page.

### Related Stocks

- [DARE.US](https://longbridge.com/en/quote/DARE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)